Hydroxyurea Medac

Hydroxycarbamide, the active ingredient in Hydroxyurea Medac, is a ribonucleotide reductase inhibitor presented as an oral tablet for oral use. It is employed to manage sickle cell disease and selected hematologic malignancies in adult patients.

GNH USA supplies Hydroxyurea Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with established quality assurance processes and regulatory compliance across EU and global markets. The company ensures product integrity through rigorous testing and secure logistics and timely delivery.

Hydroxyurea is a ribonucleotide reductase inhibitor used in hematologic disorders and certain leukemias. - Sickle cell disease: reduces frequency of painful crises and need for blood transfusions. - Chronic myelogenous leukemia: helps control disease progression when used as part of therapy. - Polycythemia vera: lowers elevated red blood cell mass and reduces thrombotic risk. - Essential thrombocythemia: decreases platelet counts and mitigates risk of clotting events.

Hydroxyurea may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Skin hyperpigmentation - Mild bone‑marrow suppression (e.g., transient leukopenia) - Alopecia

Serious or Rare Side Effects: - Severe bone‑marrow suppression (aplastic anemia) - Renal toxicity - Hepatic toxicity - Severe cutaneous reactions such as Stevens‑Johnson syndrome - Tumor lysis syndrome (rare)

When prescribing hydroxyurea, clinicians should observe several safety precautions. - Monitor blood counts: perform regular complete blood count assessments to detect myelosuppression. - Assess renal function: evaluate serum creatinine and adjust dosing in renal impairment. - Assess hepatic function: check liver enzymes before and during therapy. - Avoid in patients with known hypersensitivity: discontinue if allergic reactions occur. - Use contraception: advise women of childbearing potential to use effective contraception during treatment. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Hydroxyurea can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy agents: may cause profound bone‑marrow suppression. - Azathioprine: additive immunosuppression increasing infection risk. - Ribavirin: combined hematologic toxicity.

Moderate Interactions (Monitor Closely): - Allopurinol: may increase hydroxyurea plasma levels. - NSAIDs: can enhance renal toxicity. - Penicillins (e.g., ampicillin): may reduce hydroxyurea clearance.